Suliman Al-Fayoumi

Dr. Al-Fayoumi has over 23 years of experience in regulatory science and the pharmaceutical industry including experience in clinical pharmacology, biopharmaceutics, pharmacology, toxicology and translational sciences. In addition, Dr. Al-Fayoumi spent 8 years as a Senior Clinical Pharmacology and Biopharmaceutics Reviewer at the FDA, 4.5 years at Novartis Pharma, and 8 years at two small biotech companies. He has served as Adjunct Professor at Drexel University College of Medicine. Moreover, he has consulted over the past 7 years for numerous US based- and international biotech companies. He has extensive experience in designing, executing and overseeing ADME/DMPK, nonclinical pharmacology and toxicology and clinical pharmacology PK/PD study protocols/reports/programs and has received several awards recognizing his leadership abilities and outstanding work in regulatory science and contributions to drug development programs. Dr. Al-Fayoumi supported several regulatory submissions in his capacity as Clinical Pharmacologist and external consultant and has extensive experience interacting with key regulatory health authorities including US FDA, EMA & PMDA. Dr. Al-Fayoumi has also authored or co-authored over 14 peer-reviewed journal publications and co-invented 1 granted patent and 1 provisional patent application. His therapeutic area expertise includes hematology, oncology, anesthetics, pain, cardiovascular, GI, CNS, ophthalmology and metabolic disorders.